Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma

Patients with severe asthma can have eosinophilic inflammation and/or allergen sensitization. Benralizumab is an anti-eosinophilic monoclonal antibody being developed for patients with severe, uncontrolled asthma with eosinophilic inflammation.

https://ift.tt/2ItKvv2